LB Pharmaceuticals Inc Common Stock (LBRX)

US — Healthcare Sector
Peers: RCKT  AURA  ANNX  SLDB  LRMR  ALT  AUTL  DBVT  DSGN  KRRO 

Automate Your Wheel Strategy on LBRX

With Tiblio's Option Bot, you can configure your own wheel strategy including LBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LBRX
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral

Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia

Read More
image for news LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

About LB Pharmaceuticals Inc Common Stock (LBRX)

  • IPO Date 2025-09-11
  • Website https://lbpharma.us
  • Industry Biotechnology
  • CEO Zachary Prensky
  • Employees 16
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.